Dicerna offered 6 million shares at $15 each along with an underwriter option to purchase an additional 900,000. Dicerna estimates, after the deduction of underwriting discounts, commissions and estimated offering expenses, an investment of $92.9m.
They will trade on the Nasdaq as DRNA. In the initial public offering Jefferies, Leerink Partners and Stifel served as lead underwriters.
Dicerna focuses on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
This is added to the $217m in funding already raised by the company since 2010. Existing investors include Japan-based Kyowa Hakko Kirin who engage in the manufacture and sale of medical products and pharmaceuticals in Japan, and various life-science and medial investors including Abingworth, Domain Associates, Oxford Bioscience Partners and SR One the corporate venture capital arm of GlaxoSmithKline.